{"entity":{"id":"paper-mogamulizumab-relapsed-atll-phase-2-jco-2012","kind":"paper","name":"Defucosylated anti-CCR4 monoclonal antibody (KW-0761) for relapsed adult T-cell leukemia-lymphoma: a multicenter phase II study","aka":["Ishida 2012","KW-0761 phase 2"],"tldr":"The Japanese study in which the anti-CCR4 antibody mogamulizumab produced a response in half of people with relapsed adult T-cell leukaemia/lymphoma.","summary":"A multicentre phase 2 study of KW-0761 (mogamulizumab), a humanised defucosylated anti-CCR4 antibody that enhances antibody-dependent cellular cytotoxicity, in relapsed aggressive CCR4-positive adult T-cell leukaemia-lymphoma. Patients received 1.0 mg/kg intravenously once a week for eight weeks. The primary endpoint was overall response; secondary endpoints were progression-free and overall survival from the first dose.","asOf":"2026-11-03","links":[{"label":"Journal of Clinical Oncology 2012","url":"https://doi.org/10.1200/JCO.2011.37.3472"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/22312108/"},{"label":"Europe PMC","url":"https://europepmc.org/article/MED/22312108"}],"tags":["lymphoma-evidence-entities"],"related":[],"cancers":["adult-t-cell-leukaemia-lymphoma"],"sections":[],"technologies":[],"targets":["ccr4"],"drugs":["mogamulizumab"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["mogamulizumab-atll-phase-2-japan"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"journal":"Journal of Clinical Oncology","year":2012,"doi":"10.1200/JCO.2011.37.3472","pmid":"22312108","authors":"Ishida T, Joh T, Uike N, et al.","paperType":"observational","findings":["Of 28 patients enrolled, 27 received at least one infusion.","Objective responses were seen in 13 of 26 evaluable patients, including eight complete responses: overall response 50 per cent (95 per cent confidence interval 30 to 70).","Median progression-free survival was 5.2 months and median overall survival 13.7 months.","The commonest adverse events were infusion reactions (89 per cent) and skin rashes (63 per cent), manageable and reversible in all cases."],"whatItMeans":"The Japanese phase 2 evidence for mogamulizumab in relapsed disease; the 2019 international report records that the drug is approved in Japan for CCR4-positive adult T-cell leukaemia/lymphoma. The randomised study outside Japan later found a much lower confirmed response rate.","caveats":["Single arm, 27 treated patients, all in Japan.","Responses were assessed by criteria specific to this disease, so the rate is not directly comparable with other lymphomas."],"changedPractice":true,"participants":28},"route":"/key-papers/paper-mogamulizumab-relapsed-atll-phase-2-jco-2012/","neighbours":{"cancer":[{"id":"adult-t-cell-leukaemia-lymphoma","kind":"cancer","name":"Adult T-cell leukaemia/lymphoma","route":"/cancers/adult-t-cell-leukaemia-lymphoma/"}],"target":[{"id":"ccr4","kind":"target","name":"CCR4","route":"/targets/ccr4/"}],"drug":[{"id":"mogamulizumab","kind":"drug","name":"Mogamulizumab","route":"/drugs/mogamulizumab/"}],"trial":[{"id":"mogamulizumab-atll-phase-2-japan","kind":"trial","name":"Mogamulizumab phase 2 in relapsed adult T-cell leukaemia/lymphoma (Japan)","route":"/trials/mogamulizumab-atll-phase-2-japan/"}]}}